{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-149338","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2024-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.194770+00:00","generated_at":"2026-06-01T07:44:31.015924+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"J&J Phase 3 seltorexant meets all endpoints; Royalty Pharma holds mid-single-digit royalty","bullets":["J&J's Phase 3 MDD3001 trial of seltorexant met all primary and secondary endpoints in MDD with insomnia.","Seltorexant is a first-in-class orexin-2 receptor antagonist; no approved therapies exist for MDD with insomnia.","Royalty Pharma is entitled to a mid-single-digit royalty on worldwide net sales of seltorexant.","J&J previously estimated non-risk adjusted peak sales potential of $1B–$5B for seltorexant."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-149338","json":"https://secwatch.observer/filing/0001193125-24-149338.json","markdown":"https://secwatch.observer/filing/0001193125-24-149338.md","text":"https://secwatch.observer/filing/0001193125-24-149338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524149338/0001193125-24-149338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312524149338/d34372d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:44:31.015924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}